BCYC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
34.1M
+5314.5%
629.0K
-29.1%
887.0K
-98.2%
48.0M
+308.7%
11.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
34.1M
+5314.5%
629.0K
-29.1%
887.0K
-98.2%
48.0M
+308.7%
11.7M
Operating Expenses
47.5M
-13.9%
55.2M
-16.8%
66.4M
-8.7%
72.7M
-6.0%
77.3M
R&D
33.4M
-18.8%
41.2M
-15.8%
48.9M
-5.5%
51.8M
-11.4%
58.4M
SG&A
14.1M
+0.6%
14.0M
-19.7%
17.5M
-16.4%
20.9M
+10.8%
18.9M
Operating Income
-13477000
+75.3%
-54559000
+16.7%
-65482000
-165.0%
-24708000
+62.3%
-65551000
EBITDA
-12404000
+76.8%
-53492000
+16.9%
-64353000
-175.3%
-23372000
+63.4%
-63795000
Net Income
-10478000
+79.2%
-50333000
+17.2%
-60825000
-201.8%
-20154000
+65.9%
-59100000
EPS (Basic)
$-0.15
+79.2%
$-0.72
+17.2%
$-0.87
-200.0%
$-0.29
+65.9%
$-0.85
EPS (Diluted)
$-0.15
+79.2%
$-0.72
+17.2%
$-0.87
-200.0%
$-0.29
+65.9%
$-0.85
Shares (Diluted)
70.0M
+0.3%
69.8M
+0.2%
69.7M
+0.5%
69.4M
+0.1%
69.3M
Bicycle Therapeutics plc American (BCYC) — Financials